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The war metaphor has become common-
place in discussions about our endeavor
to find a cure for cancer. But beyond the
power of imagery, this analogy offers the
opportunity to highlight lessons that war-
riors of cancer can learn from the warriors
of terror: that more efficient killing of the
undesired cells may not always be better.
Evidence suggesting that drug-stressed and
dying cancer cells can drive tumor progres-
sion is almost as old as cancer therapy. But
like in warfare until recently, the primary
focus in cancer therapy has been, and still
is, on how to more efficiently kill.
Ever since President Nixon launched the
war on cancer in 1971, the war metaphor
has offered a convenient communication
tool to articulate the ups and downs of
our quest for a cure of cancer (1). The
repeated use of the war metaphor, however,
has directed our attention to the most visi-
ble activity of warfare: the use of destructive
force which, ironically, military leaders now
have recognized as a problem. They have
learned their lessons, and here is where the
parallels stop: lessons that cancer warriors
have yet to learn. Much as indiscriminate
carpet bombing has given place to laser-
guided bombing of the enemy, so are we
replacing broadly cell-killing chemother-
apy with modern “target-selective drugs”
that can take out with molecular precision
the critical proteins required for cancer
cell survival and expansion while minimiz-
ing collateral damage. Yet these celebrated
magic-bullet drugs (2) almost universally
fail to eradicate the tumor, which typically
relapses after a year or less. And when the
tumor recurs, it is more malignant and
uncontrollable than before (1).
The current hope is that with even
more precise target-selective drugs that
circumvent resistance-conferring muta-
tions and by using clever combinations
of such drugs, we will ultimately win the
long war against the evasive cancer cells
(3). Multi-pronged targeted attacks appear
plausible in cornering the tumor cells, as we
have seen in anti-viral therapy of HIV, and
could conquer drug resistance. But can-
cer cells are not rigid viral particles whose
sole means of evasion is genetic mutation.
Cancer cells are plastic. The thousands of
normal cell types in the human body, all
carrying the same genome, manifest an
enormous developmental potential. Could
cancer cell exploit such inherent devel-
opmental plasticity of metazoan cells to
adopt, without mutations, new phenotypes
to evade treatment (4)? If yes, then, more
effective killing to outrun the Darwinian
somatic evolution (5) generally thought to
drive the development of therapy resistance
in tumor cells, might be the wrong answer
to therapy failure.
Put more bluntly: what do all cancer
drug therapies have in common? Answer
1: they essentially fail to cure cancer. Again,
what do all cancer drug therapies have in
common? Answer 2: they all seek to per-
turb, mostly kill, cancer cells. Thus, by pure
logics, could killing eo ipso be the prob-
lem? In fact, all therapies fall into the broad
category of killing or arresting tumor cells,
directly through cytotoxic or differentiat-
ing therapy, or indirectly via inhibition of
angiogenesis, altering the tumor bed or
enhancing antitumor immunity.
Often, solutions to tough problems
come from thinking in a more encompass-
ing category than imagined. Perhaps, ques-
tioning the unquestioned notion that “only
a dead tumor cell is a good tumor cell”is the
first step. This is what cancer biologists and
oncologists can learn from lessons learned
in the war on terror: to think beyond killing
as many enemies as possible.
Targeted bombing in the war on terror
has only short-term benefits. Unlike tradi-
tional warfare against homogenous armies
with soldiers marching in unison, the war
on terrorists, and by analogy, the war on
cancer cells, is more akin to a guerilla war. It
is nearly impossible to specifically kill every
single one of the bad guys, not even with
precision weaponry. Sure, bombing cam-
paigns are often necessary to avert imme-
diate danger by reducing the numbers
of enemy combatants. But the inevitably
surviving terrorists will recover, regroup,
and adapt, emerging even stronger. This
is not the passive “selection” of geneti-
cally stronger fighters as modern Darwin-
ists might think, but rather the result of an
active response by the lucky survivors of
an incomplete attack in a rugged terrain.
In the same way, targeted therapy of can-
cer debulks the tumor, providing urgently
needed relief. But like the guerilla combat-
ants in the mountains, cancer cells are too
diverse and too disperse, such that high-
precision targeted attacks almost always
will allow some cancer cells to survive in the
tissue. These residual cells will re-emerge
as a recurrent tumor – this time resistant to
the drug and more malignant than before.
But the parallels between the war on terror
and the war on cancer end when it comes to
the lessons learned. In the course of history,
generals have learned a lesson that cancer
researchers have not yet learned.
In the wars on terror, military comman-
ders have now recognized that surviving a
drone attack energizes people more than
any propaganda can (6), creating new fight-
ers, more numerous and fiercer than before
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and more capable of evading bombs. Our
commanders have learned how to wield the
sharp double-edged sword that the use of
destructive force always is. This sensibility
is reflected in the parallel efforts to under-
stand history, tradition, and culture of the
enemy and in the campaigns to “win hearts
and minds” (7).
Cancer researchers have not yet pro-
ceeded to this stage of wisdom. Instead,
stuck in the category of thought that
“only a dead cancer cell is a good cell”
the majority does not pay attention to
“history, tradition, and culture” of can-
cer cells that reach back to our ancestors:
tumor cells can actively cope with the stress
inflicted by drugs by using the same evolved
developmental plasticity that endows a fer-
tilized egg cell with the enormous capacity
to develop into a complex multicellular
organism without mutating its genome.
The same phenotypic plasticity affords
stem cells the ability to respond to tissue
injury and xenobiotic threats by switching
cell states. By contrast, current explana-
tion of the inexorable development of
drug resistance is firmly anchored in the
orthodoxy of Darwinian evolution (8) that
eschews plasticity and espouses rigidity
of the genotype–phenotype relationship.
It is all about the “survival of the fittest”:
the cells that have acquired by chance a
“resistance-conferring mutation” before
the therapeutic attack are “selected for” by
the drug (9, 10). There is no room for phe-
notype plasticity, let alone the cell’s active
defense against near lethal perturbations.
Then, all we need are better and more pre-
cise weapons, ideally in smartly combined
and timed deployment, to neutralize these
mutated targets.
But as we now realize, every new
target-selective drug faces the development
of drug resistance (9, 11–14). In step-
ping beyond current thinking, we need
to embrace some obvious but sidelined
facts, which raise the possibility that it
is indeed the very act of killing and the
intrinsic incompleteness of this act that is
the problem: attempts to kill cancer cells
in a phenotypically heterogeneous tumor
(as they all are, like a guerilla army) with
precise target-specific compounds will not
kill all target cells, resulting in cell-stress
in the surviving cells. Importantly, treat-
ment is not without influence on the cells
that we fail to kill: therapeutic intervention
represents a massive, near-death cell-stress
for the surviving cells. It triggers a phe-
notype switch to a more primitive and
resilient state – a natural, developmen-
tally immature and perhaps evolutionary
ancient cell state (15) that is latently present
in the theoretical space of gene expres-
sion programs. Such immature states epit-
omize what we now recognize as “can-
cer stem cell” (15–21). The emergence of
resistant cells reflects a non-genetic phe-
notype switch induced by the treatment
in individual cells and not a cell pop-
ulation shift due to the expansion of a
preexisting clone with distinct properties
that allowed it to survive (22). What looks
like a violation of the Darwinian princi-
ple, which prohibits active “adaptation” to
a stressor by the individual as source of
evolutionary innovation, may actually be
the functional reactivation of an ancient
program deeply encoded in every cells’
genome that protects them from natural
stressors (15, 23). This explains why as
sophisticated survival and defense mech-
anisms as mitogen-independent cell pro-
liferation, hypoxia resistance, DNA dam-
age tolerance, invasion, migration, cell-
detoxification, immune evasion, etc. arise
in such short time soon after treatment
(24). These complex cellular programs are
barely explainable by Darwinian selection
of random mutations (22). Instead, the
physiological, “Lamarckism-like” cellular
adaptation permits a short-term expan-
sion, buying time for cells to accumulate
genetic mutations in subsequent cell gen-
erations that could lead to genetic fixation
of these new traits (4, 24). Modern evolu-
tion biologists who think beyond Darwin
appreciate that phenotypic, non-genetic
plasticity may precede Darwinian selection
of rigid mutants (25).
But now, it gets worse: the surviv-
ing cancer cells, which have endured a
non-lethal blow are not only individually
strengthened by the toxic molecules but
are surrounded by massive cell death of
its less lucky neighbors. And dead cells
release alarmins (26), a distress signal,
which induces cell-defense mechanisms
among the surviving cells and also stim-
ulates inflammation (26). These micro-
environmental disturbances can trigger
a primordial adaptive and reparative
response in the tissue (26–28) alongside an
increase of “stemness” character of tumor
cells (19, 20, 22, 29, 30), much as villagers,
including non-combatant civilians who
survive a bombing campaign, are alerted
by their injured neighbors and strength-
ened in their own resolve to counter
future attacks. Invading inflammatory
cells, evolved to repair the injured tissue,
secrete growth factors that stimulate angio-
genesis as well as tumor cells. Old experi-
ments show that injecting killed cells along
with the usual live tumor cells to model an
animal tumor dramatically boosts tumor
growth (31). Therapy-induced death of
some of their own thus triggers a resistance
movement of the entire cell community –
just as in the war against terrorists.
Summarizing a new principle, we
can say that in addition to relying on
Charles Darwin’s scheme of “survival of
the fittest ”(32), which operates at longer
time scales, tumor cells individually fol-
low Friedrich Nietzsche’s scheme: “What
does not kill me makes me stronger”(33).
This principle permits survival in the short
term, winning time for true Darwinian
evolution to take effect. Since Nietzsche’s
scheme involves a phenotype switch to
an ancient, resilient, stress-coping state,
it accounts for why recurrent tumors are
invariably more aggressive in many more
ways than just with respect to the selec-
table trait of drug resistance. Thus, the
inevitable non-genetic cell heterogeneity
entails incompleteness of killing, which
in turn permits Nietzsche’s principle of
emboldening the surviving, stressed cells
to take place – amplified by cell–cell com-
munication. This active response of tumor
cells as a coherent population makes it hard
to eradicate tumor cells and win the war on
cancer.
The military has learned its lessons. The
recent war on terrorism has illuminated
its capability to avoid groupthink and to
think in a more encompassing category.
Even more, it has learned to learn from
past failures. This process has been insti-
tutionalized by the creation of the aptly
named Center for Army Lessons Learned,
CALL (34).
It is time for a (wake-up) CALL equiv-
alent among cancer warriors. We cancer
researchers have not learned, let alone
learned to learn, from the war on can-
cer. The climate of thought at the National
Cancer Institute (NCI) for instance is such
that it still promotes the view that more
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killing, with more powerful and more pre-
cise weapons, is the way to go. And the
tender calls for funding more innovative
research by some of its wiser leaders are
drowned by the groupthink of the peer-
review system that automatically filters out
“outside-the-box” applications for research
funding. To escape this incestuous sys-
tem of mutual intellectual confirmation,
we need to complement the reflex to scan
cancer genomes for drug targets with the
reflection on the deeper“culture”of cancer.
We need to explicitly ask: Why are we losing
the war on cancer? What are the mech-
anisms of treatment failure? Whence the
enormous non-genetic plasticity of tumor
cells?
A specific solution may be to minimize
the active cellular stress response while
attacking the cells. Signaling pathways that
mediate this stress response that“makes the
non-killed cells stronger,” such as the Wnt
pathway (22, 35), could be blocked prior to
standard cytocidal therapy – as the equiv-
alent to avoiding provocation and building
political support in the countries that host
the terrorists.
Cynics may now inject: we are not win-
ning the war on terror – how then can
the military serve as an example for the
war on cancer? We may not be winning
but with minimal use of force along with
careful politics, we do contain terrorism
reasonably well, to a level that is compat-
ible with normal life for most of us. If only
in cancer research, we could learn to learn
and see that killing may only breed more
violent response. Then, as some oncol-
ogists envision (36), by taking a gentler
approach, such as “maintenance therapy”
(37) and by blocking cell-stress response,
we may one day safely drag out our patients’
war on their cancer – like we do in the
war on terrorism: far into unforeseeable
future, turning it into a well-tolerated,
barely unnoticed chronic ill.
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